
0:00
24:29
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference.
Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.
Weitere Episoden von „Lung Cancer Considered“
Verpasse keine Episode von “Lung Cancer Considered” und abonniere ihn in der kostenlosen GetPodcast App.